Black Diamond Therapeutics (BDTX) Change in Accured Expenses (2019 - 2026)

Black Diamond Therapeutics (BDTX) has 8 years of Change in Accured Expenses data on file, last reported at -$3.6 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 52.83% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.7 million (down 81.91% YoY) and the FY2025 annual result came in at -$1.4 million, down 87.04% from the prior year.
• Change in Accured Expenses slipped to -$3.6 million in Q1 2026, from $582000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.2 million in Q3 2023 to a low of -$3.6 million in Q1 2026.
• A 5-year average of -$451941.2 and a median of -$1.5 million in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 1014.75% — and 2025, when it plunged 226.97%.
• Tracing BDTX's Change in Accured Expenses over 5 years: stood at -$1.9 million in 2022, then surged by 252.45% to $2.9 million in 2023, then plunged by 176.71% to -$2.3 million in 2024, then jumped by 125.72% to $582000.0 in 2025, then plunged by 716.32% to -$3.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.6 million (Q1 2026), $582000.0 (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.